547 related articles for article (PubMed ID: 26193978)
1. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.
Sakurai Y; Mori Y; Okamoto H; Nishimura A; Komura E; Araki T; Shiramoto M
Aliment Pharmacol Ther; 2015 Sep; 42(6):719-30. PubMed ID: 26193978
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study).
Takeuchi T; Furuta T; Fujiwara Y; Sugimoto M; Kasugai K; Kusano M; Okada H; Suzuki T; Higuchi T; Kagami T; Uotani T; Yamade M; Sawada A; Tanaka F; Harada S; Ota K; Kojima Y; Murata M; Tamura Y; Funaki Y; Kawamura O; Okamoto Y; Fujimoto K; Higuchi K
Aliment Pharmacol Ther; 2020 Mar; 51(5):534-543. PubMed ID: 31990424
[TBL] [Abstract][Full Text] [Related]
3. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers.
Yamasaki A; Yoshio T; Muramatsu Y; Horiuchi Y; Ishiyama A; Hirasawa T; Tsuchida T; Sasaki Y; Fujisaki J
Digestion; 2018; 97(2):170-176. PubMed ID: 29310111
[TBL] [Abstract][Full Text] [Related]
8. Letter: promising results of Helicobacter pylori eradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy.
Inaba T; Iwamuro M; Toyokawa T; Okada H
Aliment Pharmacol Ther; 2016 Jan; 43(1):179-80. PubMed ID: 26638943
[No Abstract] [Full Text] [Related]
9. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
10. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E; Kim S; Kim B; Kim B; Kim Y; Park SS; Song GS; Yu KS; Jang IJ; Lee S
Br J Clin Pharmacol; 2022 Jul; 88(7):3288-3296. PubMed ID: 35146797
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Trial Comparing the Effects of Vonoprazan Plus Rebamipide and Esomeprazole Plus Rebamipide on Gastric Ulcer Healing Induced by Endoscopic Submucosal Dissection.
Ichida T; Ueyama S; Eto T; Kusano F; Sakai Y
Intern Med; 2019 Jan; 58(2):159-166. PubMed ID: 30210115
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
14. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
15. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial.
Tsuchiya I; Kato Y; Tanida E; Masui Y; Kato S; Nakajima A; Izumi M
Dig Endosc; 2017 Jul; 29(5):576-583. PubMed ID: 28267236
[TBL] [Abstract][Full Text] [Related]
16. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
17. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
[TBL] [Abstract][Full Text] [Related]
18. [Comparative effectiveness of the antisecretory action of rabeprazole and esomeprazole in people with rapid metabolism of proton pump inhibitors].
Morozov SV; Tsodikova OM; Isakov VA; Gushchin AE; Shipulin GA
Eksp Klin Gastroenterol; 2003; (6):58-63, 154. PubMed ID: 15065530
[TBL] [Abstract][Full Text] [Related]
19. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
[TBL] [Abstract][Full Text] [Related]
20. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii.
Nadatani Y; Watanabe T; Suda W; Nakata A; Matsumoto Y; Kosaka S; Higashimori A; Otani K; Hosomi S; Tanaka F; Nagami Y; Kamata N; Taira K; Yamagami H; Tanigawa T; Hattori M; Fujiwara Y
Sci Rep; 2019 Nov; 9(1):17490. PubMed ID: 31767915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
